Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.56 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PRKCB | P05771 | 11/20 | 0.53 |
| ▸ | PRKCA | P17252 | 11/20 | 0.53 |
| ▸ | PRKCG | P05129 | 10/20 | 0.53 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677138 | 0.82 | GSK3B (0.59) | GSK3BCAMK2DPRKCBPRKCAPRKCG | |
| SCHEMBL3784374 | 0.78 | PRKCA (0.76) | GSK3BCAMK2DTSHRPRKCBPRKCA | |
| SCHEMBL5757131 | 0.78 | GSK3B (0.65) | GSK3BCAMK2DPRKCBPRKCAPRKCG | |
| SCHEMBL3779590 | 0.77 | GSK3B (0.79) | GSK3BCAMK2DPRKCBPRKCAPRKCG | |
| SCHEMBL3781580 | 0.77 | GSK3B (0.66) | GSK3BPRKCBPRKCAPRKCG | |
| SCHEMBL3774788 | 0.76 | GSK3B (0.80) | GSK3BCAMK2DPRKCBPRKCAPRKCG | |
| SCHEMBL4339857 | 0.76 | GSK3B (0.55) | GSK3BCAMK2DPRKCBPRKCAPRKCG | |
| SCHEMBL5759900 | 0.76 | GSK3B (0.80) | GSK3BCAMK2DPRKCBPRKCAPRKCG | |
| SCHEMBL13166904 | 0.75 | CAMK2D (0.78) | GSK3BCAMK2DPRKCBPRKCAIDH1 | |
| SCHEMBL6984319 | 0.74 | GSK3B (0.78) | GSK3BCAMK2DPRKCBPRKCAPRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| EP-1513520-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2004-03-18 | — | — | US | disclosed |
| WO-2003103663-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | GSK3B 880/4885CAMK2D 66/4885HSD17B10 2869/4885 |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885CAMK2D 66/4885HSD17B10 2869/4885 |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885CAMK2D 66/4885HSD17B10 2869/4885 |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885CAMK2D 66/4885HSD17B10 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.